Medicus Pharma Ltd. Common Stock
MDCXMedicus Pharma Ltd. is a pharmaceutical company involved in the development, manufacturing, and marketing of healthcare products. The company focuses on providing medicines and healthcare solutions across various therapeutic areas, aiming to improve patient outcomes.
Company News
Medicus Pharma is developing innovative treatments for prostate and skin cancers, including a dissolvable microneedle patch for basal cell carcinoma and a next-generation hormone deprivation therapy with reduced cardiovascular risks.
The cartoning machines market is expected to grow from $8.30 billion in 2024 to $13.58 billion by 2034, driven by the increasing adoption of automation and sustainable packaging solutions across various industries.
Medicus Pharma Ltd. has received Minor Use in Major Species (MUMS) designation from the FDA for its doxorubicin-containing microneedle array (D-MNA) patch to treat external squamous cell carcinoma (SCC) in horses. This designation provides the company with a 7-year period of exclusive marketing following approval.
